The global recombinant follicle-stimulating hormone market is anticipated to grow at a significant CAGR of 2.5% during the forecast period (2022-2028). Female infertility and male hypogonadism are both treated with the recombinant follicle-stimulating hormone. It is prescribed to those women who are troubling during ovulation or who are undergoing reproductive treatments, such as IVF. It also aids […]
